SignPath Pharma (Salt Lake City UT) today announced the first commercial out-license of its proprietary CorreQT technology platform. SignPath entered into an agreement with Rain Therapeutics (Newark CA), which licenses SignPath’s CorreQT technology for use in conjunction with Rain’s proprietary lead compound, Tarlox® (tarloxotinib,) a potent pan-ErbB inhibitor in development as a treatment in various cancer indications. SignPath’s CorreQT technology is a novel, patented, platform that eliminates cardiac arrhythmia (QT prolongation) which is a common side effect of many drugs. The CorreQT technology has been shown to effectively eliminate these cardiac side effects without negatively impacting the efficacy or pharmacokinetics of the drug target. "We're excited to embark on a partnership to evaluate Signpath's CorreQT technology," said Avanish Vellanki, chairman and chief executive officer of Rain Therapeutics. "Initial non-clinical data have been very encouraging." The Rain/SignPath license agreement provides for payments of up to $78 million upon achievement of development and commercial milestones, along with royalties on commercial sales of Tarlox products incorporating SignPath’s CorreQT technology.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!